↓ Skip to main content

Dove Medical Press

Article Metrics

New oral antithrombotics: focus on dabigatran, an oral, reversible direct thrombin inhibitor for the prevention and treatment of venous and arterial thromboembolic disorders

Overview of attention for article published in Vascular Health and Risk Management, February 2012
Altmetric Badge

Mentioned by

twitter
1 tweeter

Citations

dimensions_citation
11 Dimensions

Readers on

mendeley
75 Mendeley
Title
New oral antithrombotics: focus on dabigatran, an oral, reversible direct thrombin inhibitor for the prevention and treatment of venous and arterial thromboembolic disorders
Published in
Vascular Health and Risk Management, February 2012
DOI 10.2147/vhrm.s26482
Pubmed ID
Authors

Christine Winchester

Abstract

Venous thromboembolism, presenting as deep vein thrombosis or pulmonary embolism, is a major challenge for health care systems. It is the third most common vascular disease after coronary heart disease and stroke, and many hospitalized patients have at least one risk factor. In particular, patients undergoing hip or knee replacement are at risk, with an incidence of asymptomatic deep vein thrombosis of 40%-60% without thromboprophylaxis. Venous thromboembolism is associated with significant mortality and morbidity, with patients being at risk of recurrence, post-thrombotic syndrome, and chronic thromboembolic pulmonary hypertension. Arterial thromboembolism is even more frequent, and atrial fibrillation, the most common embolic source (cardiac arrhythmia), is associated with a five-fold increase in the risk of stroke. Strokes due to atrial fibrillation tend to be more severe and disabling and are more often fatal than strokes due to other causes. Currently, recommended management of both venous and arterial thromboembolism involves the use of anticoagulants such as coumarin and heparin derivatives. These agents are effective, although have characteristics that prevent them from providing optimal anticoagulation and convenience. Hence, new improved oral anticoagulants are being investigated. Dabigatran is a reversible, direct thrombin inhibitor, which is administered as dabigatran etexilate, the oral prodrug. Because it is the first new oral anticoagulant that has been licensed in many countries worldwide for thromboprophylaxis following orthopedic surgery and for stroke prevention in patients with atrial fibrillation, this compound will be the main focus of this review. Dabigatran has been investigated for the treatment of established venous thromboembolism and prevention of recurrence in patients undergoing hip or knee replacement, as well as for stroke prevention in atrial fibrillation patients with a moderate and high risk of stroke.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 75 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Colombia 2 3%
France 1 1%
Netherlands 1 1%
Brazil 1 1%
Slovenia 1 1%
Unknown 69 92%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 14 19%
Other 11 15%
Student > Master 8 11%
Researcher 8 11%
Student > Doctoral Student 7 9%
Other 20 27%
Unknown 7 9%
Readers by discipline Count As %
Medicine and Dentistry 50 67%
Pharmacology, Toxicology and Pharmaceutical Science 6 8%
Agricultural and Biological Sciences 3 4%
Nursing and Health Professions 1 1%
Psychology 1 1%
Other 3 4%
Unknown 11 15%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 February 2013.
All research outputs
#3,079,507
of 4,507,144 outputs
Outputs from Vascular Health and Risk Management
#240
of 314 outputs
Outputs of similar age
#59,907
of 89,221 outputs
Outputs of similar age from Vascular Health and Risk Management
#11
of 14 outputs
Altmetric has tracked 4,507,144 research outputs across all sources so far. This one is in the 21st percentile – i.e., 21% of other outputs scored the same or lower than it.
So far Altmetric has tracked 314 research outputs from this source. They receive a mean Attention Score of 2.7. This one is in the 16th percentile – i.e., 16% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 89,221 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 21st percentile – i.e., 21% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 14 others from the same source and published within six weeks on either side of this one. This one is in the 14th percentile – i.e., 14% of its contemporaries scored the same or lower than it.